<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Gene silencing associated with promoter methylation can inactivate <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressor genes (TSG) in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>We identified RIL, a LIM domain gene mapping to 5q31, a region frequently deleted in <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) and <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), as methylated in 55 of 79 (70%) of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cell lines tested </plain></SENT>
<SENT sid="2" pm="."><plain>In a variety of <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumors</z:e>, we found RIL methylation in 55 of 92 (60%) cases, with highest methylation in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and <z:hpo ids='HP_0003003'>colon cancer</z:hpo>, and in 30 of 83 (36%) <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> samples, whereas <z:mpath ids='MPATH_458'>normal</z:mpath> tissues showed either absence or substantially lower levels of methylation, which correlates with age </plain></SENT>
<SENT sid="3" pm="."><plain>RIL is ubiquitously expressed but silenced in methylated <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> and could be reactivated by the hypomethylating agent <z:chebi fb="0" ids="50131">5-aza-2'-deoxycytidine</z:chebi> </plain></SENT>
<SENT sid="4" pm="."><plain>Restoring RIL expression in <z:hpo ids='HP_0003003'>colon cancer</z:hpo> cells by stable transfection resulted in reduced cell growth and clonogenicity and an approximately 2.0-fold increase in <z:mpath ids='MPATH_3'>apoptosis</z:mpath> following UV exposure </plain></SENT>
<SENT sid="5" pm="."><plain>In <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, RIL methylation is a marker of adverse prognosis independent of chromosome 5 and 7 deletions </plain></SENT>
<SENT sid="6" pm="."><plain>Our data suggest that RIL is a good candidate TSG silenced by hypermethylation in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
</text></document>